Mizuho Securities analyst, Vamil Divan today cut his target on Eli Lilly to $156 from $164 and maintained the firm’s Neutral rating on the equity.
The cut is based on the analyst’s take from the third quarter results in which the analyst has lowered his revenue estimates amid margin reduction to it’s product, Trulicity.
STA Research has a average target of $171 on the stock, and a consensus Strong Buy rating, The technical indicator is currently slightly bullish.